Compare CRBU & PRQR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CRBU | PRQR |
|---|---|---|
| Founded | 2011 | 2012 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 203.9M | 163.3M |
| IPO Year | 2021 | 2014 |
| Metric | CRBU | PRQR |
|---|---|---|
| Price | $1.75 | $1.52 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 6 |
| Target Price | ★ $10.00 | $7.67 |
| AVG Volume (30 Days) | ★ 1.4M | 325.2K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $5.37 | $18.44 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.66 | $1.08 |
| 52 Week High | $3.53 | $3.10 |
| Indicator | CRBU | PRQR |
|---|---|---|
| Relative Strength Index (RSI) | 50.32 | 43.96 |
| Support Level | $1.71 | $1.33 |
| Resistance Level | $2.11 | $1.58 |
| Average True Range (ATR) | 0.15 | 0.09 |
| MACD | 0.01 | 0.03 |
| Stochastic Oscillator | 36.00 | 51.43 |
Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) biopharmaceutical company dedicated to transforming the lives of patients with devastating diseases by applying its novel CRISPR platform, CRISPR hybrid RNA-DNA (chRDNA), toward the development of next-generation, genome-edited cell therapies. The company operates and manage business as one reportable operating segment, which is the business of developing a pipeline of allogeneic CAR-T and CAR-NK cell therapies. Geographically, it operates in United States and Rest of the World, of which United States derives maximum revenue.
ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics.